Использование Рекомбинантного Человеческого Эритропоэтина В Профилактике Тяжелой Анемии У Недоношенных Детей С Очень Низкой И Экстремально Низкой Массой Тела При Рождении

Problem of prophylaxis and treatment of early anemia of prematurely born infants is still very important. It's related to increase of rate of infants, surviving with very low and extremely low body weight at the time of birth. The purpose of trial was to provide an optimization of scheme of treatment of early anemia with recombinant human erythropoietin (rh-EPO, Recormon). This trial included 94 infants with very low and extremely low body weight at the time if birth. 26 infants was treated with rh-EPO 500 ME/kg once a week, and 33 infants — with rh-EPO 1000 ME/kg once a week, 35 infants was in control group. Rh-EPO was administrated by subcutaneous introduction once a week, from 3–5 day of life during 6 week. All patients receive iron in dose 4 mg/kg daily. As a result, the need in transfusion was decreased 5 times lower in group of children receiving rh-EPO 500 ME/kg weekly compared to control group. Patients, receiving rh-EPO 1000 ME/kg weekly, had no need in hemotransfusions. Key words: premature, early anemia, recombinant human erythropoietin, hemotransfusion. ( Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(2): 38-43 )